tbuckley/cabot-search huggingface dataset:
American Journal of Epidemiology, Baltimore
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of Contents
Authors: Susanna Huh, Catherine Gordon, Nicole Dombrowski, Dennis Karounos, Giuseppe Caso, Margaret Mcnurlan, Izolda Mileva, Alla Zemlyak, Dennis Mynarcik, Marie Gelato, Inos Inhibitor, Masao Kaneki, Yuji Fukushima, Shohei Shinozaki, Makiko Fukaya, Mayu Habiro, Nobuyuki Shimizu, Kyungho Chang, Shingo Yasuhara, J Jeevendra, Noriko Satoh-Asahara, Yousuke Sasaki, Hiromichi Wada, Mayu Tochiya, Azusa Iguchi, Reiko Nakagawachi, Shinji Odori, Shigeo Kono, Koji Hasegawa, Akira Shimatsu, Zobair Younossi, Munkhzul Otgonsuren, Chapy Venkatesan, Alita Mishra, Natalie Dixon, Tina Hurst, Duncan Talbot, Rex Tyrrell, Dylan Thompson, Nuntakorn Thongtang, Margaret Diffenderfer, Esther Ooi, Bela Asztalos, Gregory Dolnikowski, Stefania Lamon-Fava, Ernst Schaefer, Ayumu Hirata, Ken Kishida, Hironori Kobayashi, Hideaki Nakatsuji, Tohru Funahashi, Iichiro Shimomura, Alexander Krug, Lissy Stelzner, Ajaykumar Rao, Andrew Lichtman, Gordon Williams, Gail Adler, Jeffrey Sirota, Kim Mcfann, Giovanni Targher, Richard Johnson, Michel Chonchol, Diana Jalal
Journal: Metabolism (2013)
Genetic identification by a drug-induced flush
Authors: S. Vaisrub
Journal: JAMA (1979)

The medical profession has been accused of devoting too much attention to the diagnosis and treatment of disease and too little to preventive medicine. Most physicians would deny this accusation and defend their personal efforts to keep patients well by every means at their disposal. However, the report of Pantell and Stewart in this issue ofThe Journal(p 2272) calls into question the amount of effort that physicians in any practice setting devote to preventive medicine. The model studied was the use of the pneumococcal vaccine for patients who had been identified as being at special risk of suffering from pneumonia and were under medical care by health personnel who had been alerted to desirability of vaccination and the availability of the vaccine. The response in every practice setting was abysmally poor. The authors speculate about the reasons for this poor response, the most likely of which is an
Prolonged defibrination after a bite from a 'nonvenomous' snake
Authors: D. Cable
Journal: JAMA (1984)

The distinction between venomous, potentially dangerous snakes and snakes considered to be harmless to humans is not always clear. A man was bitten by an assumed harmless pet snake,<i>Rhabdophis subminatus</i>(the red neck keelback), that had been obtained from a pet store. The patient experienced a severe coagulopathy with life-threatening hemorrhage unresponsive to transfusion. Since this snake frequently is sold legally in the United States, we wish to alert the medical community to its potential danger and to discuss the pathophysiological mechanism by which the coagulopathy was produced. (<i>JAMA</i>1984;251:925-926)
Orbital Hemangiopericytoma
Authors: D J Coden, A Hornblass
Journal: JAMA (1990)

A 78-year-old healthy man, with a 30-year history of an increased prominence of the left eye, noted progressive proptosis of his left eye and increasing diplopia over a period of several years. Visual acuity was 20/30 in both eyes, with decreased color vision in his left eye. An afferent pupillary defect was present in his left eye. There was a left proptosis of 9 mm with decreased retropulsion. Mild ptosis and decreased ductions in all directions were present, and the left optic disc was slightly swollen. Computed tomography revealed a circumscribed mass in the left superomedial orbit (Fig 1). A lateral orbitotomy was performed, and a soft, purplish mass was excised. Pathological examination showed this lesion to be a hemangiopericytoma (Fig 2). Hemangiopericytomas are vascular tumors composed of spindle-shaped or rounded cells with indistinct cell borders, proliferating around endothelium-lined capillaries. They can occur anywhere in the body and have even
Leads from the MMWR. Multiple outbreaks of Kawasaki syndrome--United States
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PERMANENT CURE OF RHEUMATISM THROUGH MISADVENTURE.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intact antibody response to pneumococcal capsular polysaccharides in uremia and diabetes
Authors: E. A. Friedman
Journal: JAMA (1980)

To test their immune responsiveness to pneumococcal polysaccharide antigens, eight azotemic patients, ten dialysis patients, and five insulin-dependent diabetics were vaccinated with a 14-valent vaccine. When compared with nonazotemic, nondiabetic control subjects, both diabetics and uremic patients responded with normal antibody titers to each antigen type. Therefore, we are advising immunization with commercially available vaccine in our patients with diabetes, renal failure, or both, although long-term efficacy has yet to be proved. (<i>JAMA</i>244:2310-2311, 1980)
HEMORRHAGIC NEPHRITIS
Authors: Henry A. Christian
Journal: JAMA (1926)

<h3>To the Editor:</h3> —InThe Journal, April 3, in an article by George Baehr entitled "A Benign and Curable Form of Hemorrhagic Nephritis," the author says: "In the English and American literature nothing more than extremely casual references have come to my notice." Dr. Baehr appears to have missed seeing a paper by Drs. J. P. O'Hare and W. G. Walker in the<i>Atlantic Medical Journal</i>(<b>27</b>:280 [Feb.] 1924) under the title, "Hemorrhagic Nephritis," in which attention is called to this form of renal lesion. Also in the Oxford Medicine, Chapter XI, by myself and Dr. O'Hare this is discussed on pages 721 to 739. Here attention is called to the frequency of the hemorrhagic type of nephritis, forty-seven cases having been seen by us at the Peter Bent Brigham Hospital in ten years, and it having constituted 25 per cent of the nephritic cases observed among children by
For the Peace of Your Mind
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
c-met mRNA overexpression in human hepatocellular carcinoma
Authors: L Boix
Journal: Hepatology (1994)

This study was aimed at assessing the presence of c-met overexpression in human hepatocellular carcinoma and at determining whether this feature is associated with a definite clinical or pathological characteristic. Expression of c-met was determined by Northern-blot hybridization of a specific probe (human met proto-oncogene) in 18 tumoral and nontumoral liver samples obtained in 18 cirrhotic patients with hepatocellular carcinoma submitted to surgical treatment. Eight of the 18 hepatocellular carcinomas exhibited c-met overexpression, with an increase ranging between 2-fold and 10-fold when compared by densi-tometry with the surrounding liver. By contrast, in the remaining 10 cases c-met expression was almost identical to that of the surrounding nontumoral liver tissue. Overexpression of c-met was not related to either the age, sex, etiology or functional status of the underlying liver disease, or to the size of the tumor, to its differentiation degree or to the presence of pseudocapsule invasion and existence of additional neoplastic nodules. These data indicate that almost half of the human hepatocellular carcinomas exhibit c-met overexpression. Nevertheless, the biological relevance of this characteristic is not known. (Hepatology 1994;19:88-91).
A 35-year-old man with epigastric pain
Authors: R. Glickman
Journal: JAMA (1995)

<h3>Dr Daley</h3> : Mr H is a 35-year-old registered nurse who has recurrent episodes of epigastric pain. Divorced and the father of one child, he works in a local hospital and receives private health insurance through his employer. Since he was a child, Mr H has experienced intermittent pain in the epigastric area that radiates to the back. When the pain is mild, he describes it as burning, sometimes accompanied by chest heaviness or tightness. When the pain is severe, Mr H describes it as "a hot knife being pushed under my rib cage and out my back." His symptoms are aggravated by emotional stress, alcohol, cigarettes, and spicy foods. He denies nausea, vomiting, melena, hematemesis, symptoms of reflux, or anemia. He has never taken aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs). For many years, he took large quantities of antacids to relieve the pain, and sucralfate and cimetidine have also provided
Letter to the Editor Title Correction Made in Error
Authors: Gabriela Cobos, Caroline Nelson, Abeer Alsarheed, Avery Lachance, Alvaro Laga, Nicole Leboeuf, Ruth Vleugels
Journal: JAMA Dermatology (2020)

Preoperative Topical Decolonization—An Additional Strategy to Reduce Oral Antibiotic Prophylaxis for Mohs Infections?
Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke: A Randomized Controlled Trial
Authors: None The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment Investigators
Journal: JAMA (1998)

Context.—Anticoagulation with unfractionated heparin is used commonly for treatment of acute ischemic stroke, but its use remains controversial because it has not been shown to be effective or safe. Low molecular weight heparins and heparinoids have been shown to be effective in preventing deep vein thrombosis in persons with stroke, and they might be effective in reducing unfavorable outcomes following ischemic stroke.Objective.—To test whether an intravenously administered low molecular weight heparinoid, ORG 10172 (danaparoid sodium), increases the likelihood of a favorable outcome at 3 months after acute ischemic stroke.Design.—Randomized, double-blind, placebo-controlled, multicenter trial.Setting and Participants.—Between December 22, 1990, and December 6, 1997, 1281 persons with acute stroke were enrolled at 36 centers across the United States.Intervention.—A 7-day course of ORG 10172 or placebo was given initially as a bolus within 24 hours of stroke, followed by continuous infusion in addition to the best medical care. Doses were adjusted in response to anti–factor Xa activity.Main Outcome Measures.—Favorable outcome rated as the combination of a Glasgow Outcome Scale score of I or II and a modified Barthel Index of 12 or greater on a scale of 0 to 20 at 3 months or 7 days; very favorable outcome was recorded for the combination of a Glasgow Outcome Scale of I and a Barthel Index of 19 or 20 at 3 months or 7 days.Results.—At 3 months, 482 (75.2%) of 641 persons assigned to treatment with ORG 10172 and 467 (73.7%) of 634 patients treated with placebo had favorable outcomes (P=.49); 49.5% and 47%, respectively, of patients in each group had very favorable outcomes at 3 months. At 7 days, 376 (59.2%) of 635 persons given ORG 10172 and 344 (54.3%) of 633 receiving placebo had favorable outcomes (P=.07). For the same interval, 215 (33.9%) of 635 persons given ORG 10172 and 176 (27.8%) of 633 persons administered placebo had very favorable outcomes (P=.01; odds ratio, 1.36; 95% confidence interval, 1.06-1.73). Within 10 days of onset of treatment, serious intracranial bleeding events occurred in 14 patients given ORG 10172 (15 events) and in 4 placebo-treated patients (5 events) (P=.05).Conclusion.—Despite an apparent positive response to treatment at 7 days, emergent administration of the antithrombotic agent, ORG 10172, is not associated with an improvement in favorable outcome at 3 months.
Carcinoma of the Stomach
Authors: J. R. Wardell
Journal: BMJ (1865)

last about four hours at a time, and were so violenit :s to miake, her cry.She had never had any fits.She suibseqtuently had an attack of what her general medical attendant, Dr. Jeffree of Kennington, con- sidered meningitis; an(l after this she coinpletely recovered the vision of the affectecl eye.I, at the -inset, dianmosed the amlan,Lurosi-s a-s dependliiig' oni S'ome flfusion wliithini the olrb0it pressingou the optic nerve or retina; m(I I coinsider the ultimate pro- (rress of the case justifies miie in adhieriig to this diagnosis.
Abstract 3078: Tesetaxel, a novel, oral taxane, crosses intact blood-brain barrier (BBB) at therapeutically relevant concentrations
Authors: Joyce James, Kevin Tang, Thomas Wei
Journal: Cancer Research (2019)

Abstract Background: Central nervous system (CNS) metastases in cancers such as breast and lung cancer are common and associated with poor outcomes. The taxanes paclitaxel (P) and docetaxel (D) do not significantly cross the BBB (brain to plasma exposure of only 1% and 8%, respectively), making them ineffective in treating CNS metastases. Tesetaxel (T) is a novel, orally administered taxane currently in a Phase 3 study in patients with advanced breast cancer (aBC; NCT03326674). Several properties make it unique, including: oral administration with a low pill burden; a long (~8-day) terminal plasma half-life in humans, allowing infrequent dosing; no history of hypersensitivity reactions; significant activity against chemo-resistant tumors; and, unlike P and D, minimal efflux by the P-glycoprotein pump, a key element of the BBB. The in vivo tissue distribution of tesetaxel was previously investigated in mice treated with 14C-T at 4 mg/kg and sacrificed between 1-168 hours. We now report 2 additional studies in dogs and monkeys. Methods: Dogs and monkeys were dosed at 0.6 mg/kg and 1 mg/kg of 14C-T, respectively, and tissue distribution was assessed at 336 hours. These doses equate to ~44% of the 27 mg/m2 dose in the ongoing Phase 3 study. In vivo radioactivity concentrations in the cerebrum were compared to plasma concentrations and mean tumor GI50 (concentration resulting in 50% tumor growth inhibition) determined by MTT assay in 23 tumor cell lines. Results: The absolute brain concentrations of T in dogs and monkeys far exceeded both the respective plasma concentrations and the tumor GI50 (Table 1). Conclusions: In dogs and monkeys, T brain concentrations far exceed its tumor GI50 for a sustained period when administered at therapeutically relevant concentrations. The inclusion criteria for the ongoing Phase 3 study of T in patients with aBC allows for CNS metastases. Table 1:Tesetaxel CNS Levels Far Exceed Human GI50a in Dogs and Monkeys14C-T Radioactivity Concentration (ng eq./g or mL) bCerebrum Concentration/ Tumor GI50 cNCerebrum (Mean ± SD)Plasma (Mean ± SD)Cerebrum/ PlasmaDog d310.9 ± 4.00.9 ± 0.112x18xMonkey e36.5 ± 3.80.9 ± 0.27x11xaConcentration of drug required to inhibit growth by 50%b14 days after dosingcMean GI50 for T across 23 tumor cells lines = 0.6 ng/mLdSingle dose of 0.6 mg/kg (equivalent to 44% of a human dose of 27 mg/m2)eSingle dose of 1 mg/kg (equivalent to 44% of a human dose of 27 mg/m2) Citation Format: Joyce James, Kevin Tang, Thomas Wei. Tesetaxel, a novel, oral taxane, crosses intact blood-brain barrier (BBB) at therapeutically relevant concentrations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3078.
OP0142 Long-Term Safety of Etanercept and Adalimumab Compared to Methotrexate in Patients with Juvenile Idiopathic Arthritis (JIA)
Authors: J. Klotsche, M. Niewerth, E. Seipelt, G. Horneff, K. Minden
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The introduction of biologic drugs has substantially changed the treatment of children with a severe course of juvenile idiopathic arthrits (JIA). Etanercept (ETA) has been the most frequently used biologic drug in patients with JIA followed by Adalimumab (ADA). However, published data on the long-term safety of biologic drugs are limited (i) by a small number of years under drug exposure in recent studies and (ii) the lack of a biologic naive control group. <h3>Objectives</h3> To investigate the exposure-adjusted rates of serious adverse events (SAEs) and of events of special interest (ESIs) in order to evaluate the long-term safety of ETA and ADA compared to methotrexate (MTX). <h3>Methods</h3> Patients with polyarticular JIA who were prospectively observed in the national JIA biologic register BiKer and the adult JIA register JuMBO were considered for this analysis. All adverse events recorded by physicians over the whole observation period were categorized on the basis of MedDRA. Total exposure-adjusted rates (EY) for SAEs and ESIs were calculated. An event was attributed to ETA, ADA or MTX when the treatment was either ongoing or terminated in less than 3 month prior to the event. Propensity score methods were applied to model the likelihood of being treated with ETA or ADA instead of MTX. Adjusted relative risks were computed for these subgroups by means of a Poisson regression. <h3>Results</h3> A total of 2,263 patients (68% females, ETA start: 1162, ADA start: 46, MTX start: 1055) with polyarticular JIA were included into the safety analyses. Of these, 1,414 patients were ever treated with ETA (4,500 years of exposure), 320 patients with ADA (500 years of exposure) and 1,455 with MTX without a biologic DMARD (2,900 years of exposure). At the start with ETA or ADA, 78% of the patients also received MTX. The exposure-adjusted rates for SAE and ESIs, are given in the table. Three deaths occurred (0.05/100 EY) in patients who were ever treated with ETA in their disease course and one (0.04/100 EY) died in the MTX control group. The rates of malignancies between patients ever exposed to ETA or ADA compared to MTX did not significantly differ (MTX: 2, 0.07 events/100 EY, ETA: 5, 0.08 events/100 EY, ADA: 1, 0.14 events/100 EY). <h3>Conclusions</h3> This is the most comprehensive study of the long-term safety of Eta and Ada. It confirms the good tolerability of the substances reported in other studies. However, even in this large cohort the number of events is still too small to reliably estimate the risk of single events of interest. <h3>Disclosure of Interest</h3> J. Klotsche: None declared, M. Niewerth: None declared, E. Seipelt: None declared, G. Horneff Grant/research support: Joint unconditional grant from Pfizer, Abbvie and Roche, K. Minden Grant/research support: Joint unconditional grant from Pfizer and Abbvie <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4893
Antibiotic Resistance
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal